Imagine you are an equity research analyst reviewing the product portfolio of a large diversified financial conglomerate. You notice a Unit Linked Insurance Plan (ULIP) being marketed with aggressive equity-participation features, essentially functioning like a mutual fund with a life cover component. As you build your valuation model, you realize that the product’s asset management fees and investment disclosures are scrutinized under both insurance and securities frameworks.
Understanding where SEBI’s mandate ends and IRDAI’s begins is not just a regulatory formality; it is essential for assessing the operational risk and compliance overhead of the entity you are analyzing.
The regulatory overlap primarily stems from financial products that blend savings and protection, such as ULIPs or pension products. While SEBI regulates collective investment schemes and mutual funds that focus purely on market-linked returns, IRDAI oversees products where the primary underlying contract is insurance, even if the premium is invested in market-traded securities.
For an analyst, this distinction matters because it dictates the disclosure standards, the investment mandates, and the extent to which the issuer must report performance to market participants. If a company shifts its strategy toward more market-linked insurance products, its capital adequacy requirements and operational reporting will fundamentally shift, impacting your assessment of its long-term financial stability.
Consider the case of a hybrid product dispute. If an insurance-linked investment product fails to disclose risks clearly, the grievance redressal mechanism and the ultimate enforcement authority depend entirely on whether the regulator classifies the instrument as an insurance contract or a securities-related collective investment. Misinterpreting this can lead to incorrect assumptions about the legal liability the firm faces in a downturn.
When conducting due diligence, an analyst must map whether a firm’s business segment reports to the IRDAI’s ‘Policyholder Protection’ mandates or SEBI’s ‘Investor Protection’ mandates, as these create different levels of transparency and fiduciary responsibility for the issuer.
Ultimately, this overlap necessitates a dual-perspective in risk modeling. When assessing a firm with significant exposure to these ‘hybrid’ instruments, you must treat their regulatory compliance as a variable risk factor rather than a static constraint. Changes in inter-regulatory cooperation, such as the Joint Committee on Financial Conglomerates, can lead to sudden shifts in how these products are marketed or managed. By identifying the primary regulator for specific product lines, you gain a clearer view of the firm’s competitive landscape and the legal walls protecting or constraining its growth initiatives.
Nuance
Check Your Understanding
An insurance company launches a new life insurance policy where the entire premium is invested in equity shares of Nifty 50 companies, with no fixed return guarantee. Which regulatory authority holds the primary jurisdiction over this specific product?
In the context of the Indian financial sector, why does the overlap between SEBI and IRDAI present a risk-assessment challenge for equity analysts?
This is a companion read for Section 5.4 — Structure of Financial Markets in India from PASS Investment Adviser (Level 1) by Akhilesh Gururani, available on Amazon Kindle.
Copyright © 2026 HABSG Consulting